CPDR Unveils First Center Solely for Prostate Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 8
Volume 8
Issue 8

ROCKVILLE, Md-The Center for Prostate Disease Research (CPDR) has opened a new freestanding research center to consolidate its many initiatives and allow these programs to continue to develop and expand. The new site is the nation’s only facility dedicated solely to prostate disease research.

ROCKVILLE, Md—The Center for Prostate Disease Research (CPDR) has opened a new freestanding research center to consolidate its many initiatives and allow these programs to continue to develop and expand. The new site is the nation’s only facility dedicated solely to prostate disease research.

With approximately 20,000 square feet of space, the center houses basic research and molecular biology laboratories as well as a comprehensive prostate cancer patient database center; a prostate research library; a tumor tissue, DNA, RNA, cell, and serum bank; and an educational center for military health care providers.

The CPDR, established by Congress in 1991, is a Department of Defense program conducted in collaboration with the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine.

The CPDR focuses on identifying genetic prognostic markers to help physicians determine the best treatment for prostate disease and is also developing new molecular treatment strategies.

In its 8-year history, researchers at the CPDR have achieved several milestones in the battle against prostate disease. Among its many breakthroughs, the CPDR counts the discovery of the role played by several human genes in prostate cancer as well as the establishment of a landmark clinical database that will contain information on consenting prostate cancer patients treated within the military health system. This database will allow researchers to utilize previously unavailable clinical information to further their scientific studies.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content